- Report
- October 2024
- 181 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- October 2024
- 198 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- October 2024
- 194 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- August 2024
- 200 Pages
Global
From €2186EUR$2,290USD£1,831GBP
- Report
- July 2024
- 100 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- May 2024
- 150 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- October 2024
- 189 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 198 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 367 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 283 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 269 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 269 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 132 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 291 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 224 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 194 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 93 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 196 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 193 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 93 Pages
Global
From €5345EUR$5,600USD£4,478GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more